Influenza
Conditions
Interventions
Four week before inoculation of influenza vaccine and 8 weeks after inoculation, with daily ingestion of 20 pills of grifola frondosa extracts (6.825 g/day).
Four week before inoculation of influenza
Sponsors
Hokkaido Information University
Forest Products Research Institute, Forest Research Department, Local Independent Administrative Agency Hokkaido Research Organization
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects who plan to get inoculated with influenza vaccine in the current financial year. 2. Subjects who show low NK cell activity 3. Subjects who agree to participate in the current study with written informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects with serious diseases or infections such as cerebrovascular, cardiac, liver, kidney, gastrointestinal tract or condition which need immediate reporting to the authorities 2. Subjects who are suspected of acute infection morbidity from diseases such as influenza 3. Subjects who undergo treatment for chronic inflammatory diseases autoimmune diseases or allergies etc 4. Subjects who receive vaccination 12 weeks before participating in this study 5. Subjects who had been inoculated with influenza vaccine in past and showed anaphylaxis 6. Subjects who have a major surgical history such as gastrectomy, gastrointestinal suture surgery or intestinal resection etc 7. Subjects with frequent complaints of post-menopausal symptoms 8. Subjects with unusually high and/or low blood pressure, or with abnormal hematological data 9. Subjects with serious anemia 10. Subjects with a history of allergy to medicine and food (especially mushroom, eggs, chicken meat) 11. Subjects who regularly undertake medication which can affect the immune function (antibiotics, immunosuppressive drugs, anti-inflammatory drugs, anti-rheumatic drugs, antihistamines, anti-allergy drugs, lactic acid bacteria supplements etc.) Chinese herbal medicine, health food, supplements, extracts from (mushroom, seaweed, nucleic acids, yeast, lactic acid bacteria etc) 12. Heavy smokers, alcohol addicts or subjects with irregular lifestyle 13. Subjects who donate either 400ml whole blood within 12 weeks or plasma, platelets within 4 weeks or blood component within 2 weeks prior to this study 14. Subjects who are pregnant or under lactation or ones who would expect to be pregnant during the study 15. Subjects who participate in other clinical trials within the last one month prior to the current clinical trial 16. Subjects who are ineligible due to physician's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Influenza antibody titer, Natural Killer cell activity | — |
Secondary
| Measure | Time frame |
|---|---|
| IgG, IgM, defferential leukocyte count, IL-12, VAS, frequency of appearance of cold-like symptoms | — |
Countries
Japan
Contacts
Public ContactDir. Prof. Jun Nishihira, M.D.
Hokkaido Information University Health Information Science Center
Outcome results
None listed